No Data
No Data
Insider Sale: Director at $ACLX (ACLX) Sells 1,400 Shares
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Promising Outlook for Arcellx Inc: Anito-cel Therapy Positioned as a Safer Alternative With Strong Market Potential